reviewchronic obstructive pulmonary diseasetreatmentbronchodilatorsthiotropium bromidedisease modificatioобзорхроническая обструктивная болезнь легкихлечениебронходилататорытиотропия бромидмодификация заболевани1.Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2006. www.goldcopd.org/2.Buist A. S., McBurnie M. A., Vollmer W. M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750.3.Mannino D. M., Нота D. M., Akinbami L. J. et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveill. Summ. 2002; 51: 1-16.4.Celli B. R., MacNee W., ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD; a summary of the ATS/ERS position paper. Eur. Respir. J. 2004; 23: 932-946.5.Celli B. R. Chronic obstructive pulmonary disease: From unjustified nihilism to evidence-based optimism. Proc. Am. Thorac. Soc. 2006; 3: 58-65.6.Anzueto A. Disease modification in chronic obstructive pulmonary disease. Clin. Chest Med. 2007; 28: 609-616.7.Mahler D. A., Criner G. J. Assessment tools for chronic obstructive pulmonary disease. Do newer metrics allow for disease modification? Proc. Am. Thorac. Soc. 2006; 4: 507-511.8.O'Donnell D. E. Assessment of bronchodilator efficacy in symptomatic COPD: Is spirometry useful? Chest 2000; 117: 42-47.9.O'Donnell D. E., Lam M., Webb K. A. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 542-549.10.Черняк А. В., Авдеев С. H., Пашкова Т. Л., Айсанов З. Р. Бронходилатационный тест у больных с хронической обструктивной болезнью легких. Пульмонология 2003; 1: 50-56.11.Macklem Р. Т. Hyperinflation. Am. Rev. Respir. Dis. 1984; 129: 1-2.12.Milic-Emili J. Dynamic pulmonary hyperinflation and intrinsic PEEP: consequences and management in patients with chronic obstructive pulmonary disease. Recent Progr. Med. 1990; 81: 733-737.13.O'Donnell D. E., Webb K. A. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am. Rev. Respir. Dis. 1993; 148: 1351-1357.14.Rabe K. F. Improving dyspnea in chronic obstructive pulmonary disease. Optimal treatment strategies. Proc. Am. Thorac. Soc. 2006; 3: 270-275.15.Casanova C., Cote C., de Torres J. P. et al. The inspiratory to total lung capacity ratio predicts mortality in patients with COPD. Am. J. Respir. Crit. Care Med. 2005; 171: 591-597.16.Parker С. M., Voduc N., Aaron S. D. et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur. Respir. J. 2005; 26: 420-428.17.Stevenson N. J., Walker P. P., Costello R. W. et al. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 172: 1510-1516.18.Nuralieva G., Avdeev S., Cherniak A., Chuchalin A. Incidence and time course of expiratory flow limitation in patients with acute exacerbation of COPD. Eur. Respir. J. 2006; 28 (suppl. 50): 172s.19.Cooper C. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on the exercise and function. Am. J. Med. 2006; 119: S21-S31.20.Panning C. A., DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 2003; 23: 183-189.21.Casaburi R., Briggs D. D. Jr., Donohue J. F. et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD. A 13-week multicenter trial. Chest 2000; 118: 1294-1302.22.Casaburi R., Mahler D. A., Jones P. W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.23.Donohue J. F., van Noord J. A., Bateman E. D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.24.Brusasco V., Hodder R., Miravilles M. et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.25.O'Donnell D. E., Fluge Т., Gerken F. et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23: 832-840.26.Casaburi R., Kukafka D., Cooper С. B. et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809-817.27.Tonnel А. В., Perez Т., Grosbois J. M. et al. Improvement in HRQoL of COPD patients after 9 months' treatment with tiotropium bromide: use of a new scale for daily medical practice. Eur. Respir. J. 2005; 26: 290s.28.Niewoehner D. E., Rice K., Cote C. et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once daily inhaled anticholinergic bronchodilator - a randomized trial. Am. Intern. Med. 2005; 143: 317-326.29.Maltais F., Hamilton A., Marciniuk D. et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128: 1168-1178.30.Dusser D., Bravo M.-L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 2005; 27: 547-555.31.Verkindre C., Bart F., Aguilaniu B. et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006; 73: 420-427.32.Beeh К. M., Beier J., Buhl R. et al. Wirksamkeit von Tiotropiumbromid (Spiriva) bei verschiedenen Schweregraden der chronisch-obstruktiven Lungenerkrankung (COPD). Pneumologie 2006; 60: 341-346.33.Johansson G., Lindberg A., Romberg K. et al. Bronchodilator efficacy of tiotropium (TIO) in patients with mild COPD. Eur. Respir. J. 2006; 28 (suppl. 50): E3614.34.Freeman D., Lee A., Price D. Efficacy and safety of tiotropium in COPD patients in primary care - the SPiRiva Usual CarE (SPRUCE) study. Respir. Res. 2007; 8: 45 doi: 10.1186/1465-9921-8-45.35.Powrie D. J., Wilkinson Т. M. A., Donaldson G. C. et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur. Respir. J. 2007; 30: 472-478.36.Chan С. K., Maltais F., Sigouin C. et al. SAFE Study Group. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can. Respir. J. 2007; 14: 465-472.37.Moita J., Barrbara C., Cardoso J. et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm. Pharmacol. Ther. 2008; 21: 146-151.38.van Noord J. A., Bantje T. A., Eland M. E. et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55: 289-294.39.Vincken W., van Noord J. A., Greefhorst A. P. M. et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209-216.40.Hsu J.-Y., Perng R.-P., Lu J.-Y. et al. Double-blind randomized parallel group study comparing the efficacy and safety of tiotropium and ipratropium in the treatment of COPD patients in Taiwan. J. Formos. Med. Assoc. 2006; 105: 708-714.41.Voshaar Т., Lapidus R., Maleki-Yazdi R. et al. A randomized study of tiotropium Respimats Soft Mist™ Inhaler vs. ipratropium pMDI in COPD. Respir. Med. 2008; 102: 32-41.42.Briggs D. D. Jr., Covelli H., Lapidus R. et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm. Pharmacol. Ther. 2005; 18: 397-404.43.Adams S. G., Anzueto A., Briggs D. D. et al. Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respir. Med. 2006; 100: 1495-1503.44.Celli В., Wallack R. Z., Wang S. et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-1748.45.Breekveldt-Postma N. S., Koerselman J., Erkens J. A. et al. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir. Med. 2007; 101: 1398-1405.46.Rennard S. I., Anderson W., ZuWallack R. et al. Use of a long-acting inhaled p2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1087-1092.47.Fletcher С. M., Elmes P. C., Wood С. H. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br. Med. J. 1959; 1: 257-266.48.Mahler D., Weinberg D., Wells C., Feinstein A. The measurement of dyspnea: contents, interobserver agreement and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.49.Oga Т., Nishimura K., Tsukino M. et al. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir. Med. 2007; 101: 146-153.50.Jones P. W., Quirk F. H., Baveystock С. M., Littlejohns P. A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am. Rev. Respir. Dis. 1992; 145: 1321-1327.51.Mahler D. A., Tomlinson D., Olmstead E. M. et al. Changes in dyspnea, health status, and lung function in chronic airway disease. Am. J. Respir. Crit. Care Med. 1995; 151: 61-65.52.Tashkin D., Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123: 1441-1449.53.O'Donnell D. E., Mahler D. A. Effect of bronchodilators and inhaled corticosteroids on dyspnea in COPD. In: Mahler D. A., O'Donnell D. E., eds. Dyspnea: mechanisms, measurement and management. New York: Marcel Dekker; 2005. 283-299.54.Pinto-Plata V. M., Cote C., Cabral H. et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur. Respir. J. 2004; 23: 28-33.55.Cote C. G., Pinto-Plata V., Kasprzyk K. et al. The 6-min walk distance, peak oxygen uptake, and mortality in COPD. Chest 2007; 132: 1778-1785.56.Curtis J. R., Patrick D. L. The assessment of health status among patients with COPD. Eur. Respir. J. Suppl. 2003; 41: 36s-45s.57.Reardon J. Z., Lareau S. C., Zu Wallack R. Functional status and quality of life in chronic obstructive pulmonary disease. Am. J. Med. 2006; 119 (10A): S32-S37.58.Guell R., Casan P., Sangenis M. et al. Quality of life in patients with chronic respiratory disease: the Spanish version of the Chronic Respiratory Questionnaire (CRQ). Eur. Respir. J. 1998; 11: 55-60.59.Donaldson G. C., Wedzicha J. A. COPD exacerbations: epidemiology. Thorax 2006; 61: 164-168.60.Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis. 1997; 52: 43-47.61.Washko G. R., Fan V. S., Ramsey S. D. et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 2008; 177: 164-169.62.Welte T. Acute exacerbation of chronic obstructive pulmonary disease. More a functional than an inflammatory problem? Am. J. Respir. Crit. Care Med. 2008; 177: 130-131.63.White S. R., Tse R., Marroquin B. A. Stress-activated protein kinases mediate cell migration in human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 2005; 32: 301-310.64.Wise R. A. The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression. Am. J. Med. 2006; 119 (10A): S4-S11.65.Decramer M., Celli В., Tashkin D. P. et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004; 1: 303-312.66.Scanlon P. D., Connett J. E., Waller L. A. et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the Lung Health Study. Am. J. Respir. Crit. Care Med. 2000; 161: 381-390.67.Anzueto A., Tashkin D., Menjoge S., Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm. Pharmacol. Ther. 2005; 18: 75-81.68.Murray C. J. L., Lopez A. D. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-1276.69.World Health Organization. Global initiative for chronic obstructive lung disease. Geneva: World Health Organization; 2002.70.National Center for Health Statistics. Report of final mortality statistics; 2003. Available at: http://www.nlm.nih.gov/medlineplus/healthstatistics.html.71.Groenewegen К. H., Schols A. M., Wouters E. F. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124: 459-467.72.Seneff M. G., Wagner D. P., Wagner R. P. et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. J. A. M. A. 1995; 274: 1852-1857.73.Medical Research Council Working Party. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681-686.74.Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 1980; 93: 391-398.75.Anthonisen N. R., Skeans M. A., Wise R. A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233-239.76.National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N. Engl. J. Med. 2003; 348: 2059-2073.77.Lightowler J. V., Wedzicha J. A., Elliott M. W., Ram F. S. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Br. Med. J. 2003; 326: 185-189.78.Salpeter S. R., Buckley N. S., Salpeter E. E. Meta-analysis: Anticholinergics, but not Β-agonists, reduce severe exacerbations and respiratory mortality in COPD. J. Gen. Intern. Med. 2006; 21: 1011-1019.